Patent 11071725 was granted and assigned to FORMA Therapeutics on July, 2021 by the United States Patent and Trademark Office.
This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.